Roquefort Therapeutics Plc operates as an investment company. It was formed to acquire medical biotechnology businesses that are focused on early stage opportunities to include drug and vaccine development, diagnostics, immuno-therapy, and cell and gene therapies. The company was founded on August 17, 2020 and is headquartered in London, the United Kingdom.